Agenus Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014. Agenus is a clinical-stage biopharmaceutical company developing immuno-oncology candidates, therapeutic vaccines and vaccine adjuvants.
Financial results and position
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Revenue | $0.721 million | $1.109 million |
| Research and development expense | $4.473 million | $2.554 million |
| General and administrative expense | $5.163 million | $2.892 million |
| Operating loss | $9.824 million | $4.609 million |
| Net loss | $0.358 million | $5.835 million |
| Net loss attributable to common stockholders | $0.409 million; $0.01 per share | $8.842 million; $0.35 per share |
| Net cash used in operating activities | $10.124 million | $3.895 million |
Cash and cash equivalents were $73.5 million at March 31, up from $27.4 million at year-end, principally reflecting a February public offering that generated approximately $56.0 million in net proceeds. Current assets were $75.3 million and current liabilities were $14.4 million. The company reported approximately $10.0 million of debt outstanding; balance-sheet amounts included $8.1 million of long-term debt, including its current portion, and $1.2 million of convertible notes. Gross margin is not a meaningful disclosed measure for this largely development-stage business; the filing does not provide a clear gross-margin figure.
The company reported an accumulated deficit of $649.2 million and stockholders’ equity of $63.3 million, compared with a $4.5 million stockholders’ deficit at December 31, 2013.
Material changes and unusual items
- Revenue declined approximately 35% year over year, including no service revenue in Q1 2014 versus $0.725 million in Q1 2013. Grant revenue was $0.029 million, while research and development revenue was $0.692 million.
- R&D expense rose 75% and G&A expense rose 79%. Management attributed the increases primarily to higher personnel and compensation costs, checkpoint-program spending, and professional fees related to corporate activity and the 4-Antibody acquisition.
- Reported net loss improved substantially, but results included $9.822 million of non-operating income, principally from a reduction in the fair value of the contingent royalty obligation. The reduction related primarily to GSK’s termination of a Phase 3 non-small-cell lung cancer vaccine trial. Separately, a $0.909 million increase in the fair value of acquisition-related contingent consideration was recorded as an operating expense.
- In February, Agenus acquired 4-Antibody AG for an estimated purchase price of approximately $19.8 million, including common shares valued at $10.1 million and contingent consideration. The acquisition added the Retrocyte Display technology and six preclinical checkpoint-antibody programs. Purchase accounting remained preliminary.
- Q1 financing cash flow included $56.7 million of net equity proceeds, while operating cash use increased to $10.1 million. Cash burn averaged approximately $3.4 million per month during the quarter, according to the risk-factor discussion.
Outlook, commentary and risks
- Management said cash at March 31, together with potential license, supply and collaboration proceeds, was expected to fund current plans through the first half of 2015. Agenus expected to seek additional funds before exhausting its resources and could pursue partnerships, asset sales, debt or equity financing, or spending reductions. It warned that unavailable financing or prolonged losses could threaten continued operations.
- No quantified revenue or earnings guidance was provided. The company expected significant losses and substantial additional R&D spending; the cost and timing of development and potential commercial cash inflows could not be reliably estimated.
- Agenus planned to identify development candidates for four additional checkpoint programs during 2014 and aimed to be positioned to file INDs on at least four candidates within two years. It had selected two GITR agonists and one CTLA-4 antagonist for IND-enabling development.
- Additional HerpV Phase 2 results, including booster-injection assessment, were anticipated in Q2 2014. Management noted that further HerpV development depended on the results and the availability of funding or a partner. Prophage studies faced enrollment and development uncertainties, and most QS-21 programs depended on licensees’ trial, regulatory and commercialization success.
- After quarter-end, Agenus announced an April collaboration with Merck to discover and optimize antibodies against two undisclosed checkpoint targets. Merck would lead clinical development and commercialization; Agenus could receive milestone and royalty payments.
- Key risks include continued cash consumption and financing dependence; clinical, regulatory and manufacturing uncertainty; reliance on partners and licensees; competition and intellectual-property challenges; and integration of 4-Antibody. The company had $8.9 million of contingent royalty obligations and $10.6 million of acquisition-related contingent purchase consideration, both valued using significant unobservable assumptions.
- On April 24, 2014, the company increased authorized common shares from 70 million to 140 million. Disclosure controls were reported effective; integration of 4-Antibody’s financial controls was still underway.
Key facts for investors to verify
- Whether the stated cash runway through the first half of 2015 remains achievable given operating cash use, development plans and financing needs.
- The assumptions behind the contingent royalty valuation and the impact of further partner trial cancellations or changes in expected royalty streams.
- Progress on 4-Antibody integration, final purchase-price allocation, checkpoint candidate selection and planned IND-enabling work.
- HerpV follow-up data, Prophage trial enrollment, and the progress and outcomes of QS-21 partner programs.
- Debt repayment and covenant requirements, potential contingent acquisition payments, and the dilution implications of expanded authorized shares and future financing.